Commonwealth Equity Services LLC Sells 1,827 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Commonwealth Equity Services LLC cut its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 7.1% in the 2nd quarter, Holdings Channel reports. The firm owned 23,868 shares of the company’s stock after selling 1,827 shares during the period. Commonwealth Equity Services LLC’s holdings in Takeda Pharmaceutical were worth $309,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Principal Securities Inc. acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter worth $28,000. Wells Fargo & Company MN increased its holdings in Takeda Pharmaceutical by 1.7% in the fourth quarter. Wells Fargo & Company MN now owns 774,552 shares of the company’s stock valued at $11,053,000 after purchasing an additional 12,756 shares during the period. Aigen Investment Management LP acquired a new stake in Takeda Pharmaceutical during the 4th quarter worth about $197,000. Catalytic Wealth RIA LLC acquired a new stake in Takeda Pharmaceutical during the 4th quarter worth about $233,000. Finally, Gold Investment Management Ltd. acquired a new stake in Takeda Pharmaceutical during the 4th quarter worth about $994,000. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Price Performance

TAK stock opened at $14.91 on Tuesday. The stock has a market capitalization of $47.19 billion, a PE ratio of 27.11, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54. The company’s 50-day moving average is $14.35 and its 200-day moving average is $13.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $16.06.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. The business had revenue of $7.75 billion for the quarter. Equities research analysts expect that Takeda Pharmaceutical Company Limited will post 1.63 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.